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ABSTRACT
Cardiac amyloidosis describes a clinical disorder caused by infiltration of abnormal insoluble fibrils in the heart, characterized 
by progressive heart failure and a grave prognosis. Pleural effusion in cardiac amyloidosis may represent a sign of heart fail-
ure, but it can also result from pleural infiltration of amyloid, manifested by recurrent large fluid accumulations. Recently, 
the role of vascular endothelial growth factor (VEGF) has been implicated in the pathogenesis of refractory pleural effusion. We 
report a case of a 53 year-old female patient with cardiac amyloidosis who presented with recurrent accumulation of large pleu-
ral effusions. She was initially treated with high dose loop diuretics, but the pleural effusion persisted, with the daily amount of 
drainage averaging 1 L/day. Accumulation of pleural fluid did not subside after 3 cycles of melphalan/prednisolone therapy. 
After the introduction of bevacizumab, an anti-VEGF antibody, the amount of pleural effusion decreased significantly. Effica-
cy of anti-VEGF therapy for refractory pleural effusions needs to be defined through further studies. (Korean Circ J 2010; 
40:671-676)
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Introduction
Amyloidosis is a clinical disorder caused by extracellular 
deposition of insoluble abnormal fibrils, derived from aggre-
gation of misfolded normally soluble protein.
1) Cardiac infil-
tration of amyloid fibril results in progressive cardiomyopathy 
with a grave prognosis.
2)3) A prominent clinical feature of car-
diac amyloidosis is a syndrome of heart failure, characterized 
by restrictive hemodynamics and progressive deterioration of 
systolic function. Pleural effusion can develop as a consequence 
of heart failure, but sometimes it is disproportionate to the de-
gree of heart failure and is resistant to conventional diuretic 
therapy. The latter complication occurs most often in primary 
systemic (AL) amyloidosis.
4) Refractory pleural effusions are 
difficult to manage and associated with a poor prognosis.
4) 
Recently, vascular endothelial growth factor (VEGF) has been 
implicated to play a role in both malignant and nonmalig-
nant pleural effusions through its ability to regulate vascular 
permeability.
5-8) Thus, a therapeutic approach employing anti-
VEGF agent might emerge as a potential alternative for man-
aging refractory pleural effusions complicating systemic amy-
loidosis. Here, we report a case of cardiac amyloidosis in which 
recurrent pleural effusion could be managed by therapy with 
bevacizumab, an anti-VEGF antibody.
Case
A 53 year-old female patient was transferred to our cardiol-
ogy department for the evaluation of hypotension and dyspnea 
after successful treatment for recombinant tissue-type plas-
minogen activator for acute right middle cerebral artery infarc-
tion. She reported previous episodes of dyspnea and had been 
diagnosed with cardiac hypertrophy one year previously. But 
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she denied any prior history of coronary heart disease, hyper-
tension, diabetes, or pulmonary diseases. She had not been tak-
ing any medication for her cardiac condition. 
On transfer, examination revealed blood pressure 90/60 
mmHg, heart rate 100/min, body temperature 36.4˚C, and re-
spiration rate 22/min. Her face was puffy, and her jugular vein 
was distended with an estimated pressure of 18 cm H2O. Car-
diac sounds were regular, and a gallop sound was not audible. 
Breath sounds were markedly diminished in the lower half of 
right lung field. The liver was palpable about 5 cm below the 
right costal margin. There was marked pitting edema in both 
lower extremities. 
The electrocardiography showed low voltage in the limb 
leads and a small R wave amplitude across the precordial leads 
(Fig. 1). The chest film demonstrated moderate cardiomegaly, 
interstitial congestion and marked pleural effusion in the right 
lung field (Fig. 2A). Initial laboratory studies revealed normal 
ranges of renal function test and liver function test, mildly el-
evated troponin-I (0.52 ng/mL: normal <0.1 ng/mL), and mar-
kedly elevated BNP (1,867 pg/mL: normal <100 pg/mL). Serum 
protein was 6.2 g/dL (normal 6.6-8.4 g/dL), albumin 3.5 g/dL 
(normal 3.8-5.2 g/dL), and 24 hours urine protein 4.5 g/day 
(normal 0.03-0.12 g/day). On echocardiography, the septal 
and free walls of the left ventricle were both moderately thick-
ened (13 mm and 14 mm, respectively), but the left ventricu-
lar cavity dimension was not enlarged. Left ventricular wall mo-
tion was active, with an estimated ejection fraction in the 65-
69% range. Two-dimensional evaluation of the inferior vena 
cava and Doppler estimation of tricuspid regurgitation re-
vealed elevated right atrial pressure (>20 mmHg) and systolic 
pulmonary artery pressure (>54 mmHg). Doppler analysis of 
transmitral inflow showed restrictive pattern with high E/A 
ratio (2.3) and short deceleration time (119 m/s). Tissue Dop-
pler of mitral annular diastolic velocity (E’) was markedly re-
duced (2.5 cm/s), and estimated left ventricular filling pressure 
was consequently high (50 mmHg) (Fig. 3). Cardiac magnetic 
resonance imaging (MRI) revealed a late enhancement of gad-
olinium over the entire subendocardial circumference with va-
rying degree of extension into the neighboring myocardium 
(Fig. 4). This particular pattern of late gadolinium enhance-
Fig. 1. Initial standard electrocardiogram showing low voltage in the limb leads (<5 mm) and small R wave amplitude across the precordial leads.
Fig. 2. A: initial chest roentgenogram showing cardiomegaly, pulmonary congestion and pleural effusion in the right hemithorax, B: chest film 
taken 1 year after initial admission showing no sign of pleural fluid in the right hemithorax. 
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ment is regarded as a unique and sensitive feature of cardiac 
amyloidosis.
9) Taken together, these electrocardiographic, ec-
hocardiographic, and MRI findings strongly suggested a diag-
nosis of cardiac amyloidosis. The result of renal biopsy con-
firmed the diagnosis of amyloidosis. Congo-red stain of the 
specimen revealed apple green birefringence under polarized 
microscopy (Fig. 5), a finding compatible with amyloid de-
posit. Serum free-light-chain assay revealed excessive in-
crease in lambda free light chain, resulting in low kappa-to-
lambda ratio {free kappa (κ) light chain 18.6 mg/L: reference 
value 3.3-19.4 mg/L, free lambda (λ) light chain 168.9 mg/L: 
reference value 5.71-26.3 mg/L, κ/λ ratio 0.11: reference val-
ue 0.26-1.65}. Therefore, the patient was diagnosed with pri-
mary (AL) cardiac amyloidosis, with manifestations of heart 
failure, nephrotic syndrome, and massive pleural effusion. 
She was initially treated with high dose loop diuretics (intra-
venous furosemide 120 mg/day) which improved dyspnea sy-
mptoms and lower leg edema. However, the accumulation of 
pleural effusion showed no signs of abatement on her chest 
film. For the drainage, a pig-tail catheter was inserted into the 
right hemithorax. Analysis of pleural fluid revealed protein 0.6 
g/dL, albumin 0.3 g/dL, LDH 74 IU/L, and 21 nucleated cells 
(46% polymorphonuclear leukocyte, 27% lymphocyte, 20% 
monocyte and 7% histiocytes), consistent with transudative 
effusion. Repeat fluid analysis reported similar results. Pleural 
biopsies were performed, but pathological examination reveal-
ed only fibrosis without signs of amyloid deposit. She was then 
started on chemotherapy with melphalan (6 mg/m
2 for 4 days) 
and prednisolone (60 mg/m
2 for 4 days). Three cycles of che-
motherapy elicited the improvement of the kappa-to-lambda 
ratio (free κ light chain 25.8 mg/L, free λ light chain 51.7 mg/
L, κ/λ ratio 0.50), but failed to reduce the accumulation of pleu-
ral fluid (Fig. 6). Following discussion of the risk and benefits, 
bevacizumab, an anti-VEGF antibody, was chosen over che-
mical pleurodesis for management of her recurrent pleural 
effusions. Bevacizumab was scheduled to be administered by 
intravenous infusion, 5 mg/kg/day over 90 minute every 3 
weeks. After 1 cycle of bevacizumab therapy, the amount of ple-
ural drainage was markedly decreased to an average of 441 
mL/day. Another cycle of bevacizumab therapy was given 3 
weeks later. The patient objected to further chemotherapy and 
so was treated only conservatively thereafter. However, 8 weeks 
after the completion of the second bevacizumab therapy, the 
amount of pleural effusion was reduced to nearly zero despite 
a similar degree of nephrosis on follow-up (Fig. 6). Her general 
condition was also improved, and she was encouraged to am-
bulate. With respect to adverse effects of bevacizumab, there 
were no signs of bleeding or thrombosis, nor aggravation of 
proteinuria during subsequent follow-up. Chest film taken 1 
year after initial admission showed no sign of pleural effusion 
in the right hemithorax (Fig. 2B).
Discussion 
This case represents a challenging case of refractory pleu-
ral effusion associated with primary (AL) amyloidosis involv-
ing cardiac tissue. In this case, the diagnosis of cardiac amyloi-
dosis was established based upon the characteristic findings 
on echocardiography and cardiac MRI, together with histol-
ogy obtained from renal tissue, and the result of serum free-
light-chain assay. Recent MRI technique of late gadolinium 
enhancement generates distinct images for cardiac amyloido-
sis with a great sensitivity and specificity, so histologic demon-
Fig. 3. Results of echocardiographic examination. A: two-dimensional echocardiographic image (parasternal long-axis view) showing nor-
mal ventricular dimensions and concentric left ventricular wall thickening. Granular “sparkling” appearance of ventricular wall was not appar-
ent. B: Doppler signals of transmitral inflow showing restrictive pattern with high E/A ratio (2.3) and short deceleration time (119 m/s). C: tissue 
Doppler echocardiogram of mitral annulus showing markedly reduced diastolic velocity (E’) (2.5 cm/s), with elevation of estimated left ven-
tricular filling pressure (50 mmHg). 
A   B   C  
Fig. 4. Magnetic resonance images of left ventricular short axial 
view (A) and 4-chamber long-axis view (B) from post gadolinium 
delayed enhancement show diffuse subendocardial enhancement 
in both left (arrows) and right ventricles.
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stration of amyloid deposit in extracardiac tissue would obvi-
ate the need for cardiac biopsy.
9) 
Pleural effusion in cardiac amyloidosis can occur as a con-
sequence of heart failure, but in some patients with primary 
(AL) systemic amyloidosis, large pleural effusion develops, 
which is refractory to diuretic therapy and thoracentesis.
4) Pre-
sence of large, persistent pleural effusion among those patients 
is clinically significant, not only because it deteriorates the qual-
ity of life but also because it is associated with poor prognosis.
4) 
The prevalence of pleural effusion has not been clearly defined, 
but in one study 6% of 636 amyloid (AL) patients were inflict-
ed with this complication.
10) In contrast, no cases of pleural ef-
fusion were reported in 233 patients with secondary (AA) amy-
loidosis.
11) 
Mechanisms underlying pleural effusions in AL amyloido-
sis remain poorly understood. Unlike the transudative nature 
observed in usual heart failure, the chemistry of pleural effu-
sions in AL amyloidosis varied; about one third to one half of 
the cases were found to be exudative.
4)10) The extraordinarily 
Fig. 6. Average drainage of pleural effusion during the chemother-
apy. The change of the amount of drained pleural effusion during 
the chemotherapy. The patient received three cycles of oral mel-
phalan/prednisolone therapy (thin arrow indicates the start of che-
motherapy), and 2 cycles of intravenous bevacizumab at the first 
day of the fourth, and 3 weeks later (thick arrows). The average am-
ount of pleural drainage decreased significantly following the ad-
dition of bevacizumab (p<0.01) and no pleural drainage was de-
tectable 8 weeks after the completion of the second bevacizumab 
therapy. 
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Fig. 5. A: microscopic findings of renal tissue. PAS-negative eosinophilic material deposition is observed on the wall (thin arrow) of the inter-
lobular artery and glomerular mesangium (thick arrow) (PAS, ×400). B: view of renal tissue under polarizing microscopy. The interlobular artery 
shows apple-green birefringence (arrow) on Congo-red staining. C: electron microscopic findings of renal tissue showing tangles of fibrils within 
mesangial area (arrows) (EM, ×12,500). D: high power view of mesangial tangle showing haphazardly arranged fibrils (arrows) (EM, ×30,000).
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high rate of exudative effusion suggests that altered hydrostat-
ic forces may not be the principal mechanism driving pleural 
fluid accumulation. Indeed, in a study comparing 35 AL am-
yloidosis patients with pleural effusion versus 120 patients with-
out effusion, no significant differences were found in left ven-
tricular indices, pulmonary pressure, or degree of nephrosis.
10) 
Furthermore, both gross and microscopic examination of 
pleural surface identified the presence of amyloid deposit,
10)12) 
lending strong support to amyloid infiltration being a major 
factor.
In our case, the pleural effusion was transudative in both of 
2 fluid analyses. Nevertheless, the effusion did not respond to 
high dose loop diuretics, even after signs of pulmonary con-
gestion had cleared. The effusion was also refractory to 3 cycles 
of melphalan/prednisolone chemotherapy. The effusion re-
curred rapidly with daily drainage averaging 1 L/day. Refrac-
toriness of transudative effusion to conventional therapy war-
rants further discussion. The development of transudative ef-
fusion indicates that the integrity of pleural membranes is mo-
stly intact.
13) Therefore, it is conceivable that impaired pleural 
fluid absorption is a contributing mechanism. The presence of 
mesothelial stomata, intercellular openings, and rich networks 
of submesothelial lymphatics and blood vessels identify pari-
etal pleura as the principal drainage system of the pleural 
space.
14) Blockage of these drainage components by amyloid 
deposit could lead to the loss of its ability to remove fluid. How-
ever, increased fluid secretion is the principal underlying ab-
normality in the genesis of most effusions, even if obstruction 
of fluid drainage co-exists.
15) One candidate mediator for al-
tered pleural secretion might be VEGF, which enhances per-
meability of vascular and mesothelial barriers.
5)16) VEGF in-
creases capillary and venular leakage by opening the endo-
thelial intracellular junctions and by inducing fenestration 
development in endothelia.
5) Additionally, VEGF increases 
microvascular permeability by enhancing the activity of vesic-
ular vacuolar organelles, through which macromolecules ex-
travasate.
17) Increased VEGF levels have been observed in both 
the serum and pleural fluid from patients with malignant and 
non-malignant pleural effusions.
6) Although a role of VEGF 
has been emphasized mostly in exudative effusions,
5) it is con-
ceivable that VEGF might also contribute to formation of tran-
sudative effusion via the mechanisms cited above.
5)17)
Management of large pleural effusion in primary (AL) am-
yloidosis is a challenging task. Aggressive diuresis or invasive 
measures like repeated thoracentesis, pleurodesis, and thora-
coscopic interventions have only limited efficacy and risk po-
tential adverse effects. Recently, with increasing appreciation 
of the vital role of VEGF in the formation of pleural effusion, 
strategic targeting inhibition of VEGF activity is being employ-
ed as an alternative measure for managing refractory effusions. 
In a case report published in 2005, bevacizumab, an anti-VE-
GF antibody, successfully reduced pleural effusion for the first 
time in a patient with primary AL cardiac amyloidosis.
7) Fol-
lowing this report, 4 cases of successful management of refrac-
tory pleural effusions with bevacizumab were described in pa-
tients with primary systemic amyloidosis.
8) In the present case, 
recurrence of large pleural effusions was not affected by che-
motherapy, but the amount of effusion was remarkably reduc-
ed after introduction of bevacizumab therapy. It is unlikely 
that this benefit was due to the reduction of oncotic pressure, 
because the degree of nephrosis and proteinuria remained 
similar throughout the follow-up. Regarding the safety issue, 
bleeding complications or venous thrombosis were not ob-
served in this patient. Aggravations of proteinuria or heart 
failure were other concerns, but neither were observed. Thus, 
bevacizumab therapy improved the pleural effusion in this 
patient, and appeared clinically beneficial. However, the dura-
tion of observations presented in this report was relatively 
short, and further follow-up will be needed to assess the effect 
of the therapy. For patients with similar overall clinical presen-
tations, prospective studies are necessary to define the role of 
bevacizumab. This case, together with previous reports,
7)8) 
suggests the potential of bevacizumab therapy as a novel strat-
egy in patients with systemic amyloidosis and refractory pleu-
ral effusions who have few management options. 
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